ClinicalTrials.gg
TerminatedNCT02612311UNITY-CLLUpdated Dec 13, 2024Results posted

Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia

A Phase 3 interventional study of Obinutuzumab and Ublituximab in Chronic Lymphocytic Leukemia, sponsored by TG Therapeutics, Inc.. Terminated at 154 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-13.

Sponsored by TG Therapeutics, Inc. · Phase 3, Interventional, and Treatment

Why this study was terminated
Strategic/Business decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
603
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing ublituximab in Leukemia, Lymphocytic, Chronic, B-Cell — none open to participants now, 1 under way, none of them phase 3. ublituximab · Leukemia, Lymphocytic, Chronic, B-Cell.

Enrollment
Largest of 13
603 · median 51
Started
2015
with 1 other
Phase 3
2 of 13
none open now
Registered
7th of 13
by date
Lead sponsor
10 of 13
TG Therapeutics, Inc.

Among the 13 studies testing ublituximab in Leukemia, Lymphocytic, Chronic, B-Cell, this one has the largest enrollment, is one of 2 that started in 2015, is one of 2 in phase 3, and was the 7th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

None of the 13 studies testing ublituximab in Leukemia, Lymphocytic, Chronic, B-Cell is open now. The open studies under Leukemia, Lymphocytic, Chronic, B-Cell, anywhere →

About ublituximab

ublituximab: first FDA approval 2022 (BRIUMVI), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies testing ublituximab in Leukemia, Lymphocytic, Chronic, B-Cell as a file.
02

Study summary

This study evaluates the combination of ublituximab, a novel monoclonal antibody, and TGR-1202, a novel PI3K delta inhibitor compared to obinutuzumab and chlorambucil, and compared to ublituximab or TGR-1202 alone in Chronic Lymphocytic Leukemia (CLL) participants.

03

Conditions studied

  • Chronic Lymphocytic Leukemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Treatment naïve or previously treated Chronic Lymphocytic Leukemia (CLL) requiring treatment
  • (ECOG) score of 0 to 2

Exclusion criteria

Exclusion Criteria:

  • Any major surgery, chemotherapy or immunotherapy within the last 21 days
  • Evidence of virus, virus or known infection
  • Autologous hematologic stem cell transplant within 3 months of study entry. Prior Allogeneic hematologic stem cell transplant is excluded
  • Transformation of CLL to aggressive Non-Hodgkin's Lymphoma (NHL) (Richter's transformation)
  • Prior therapy with obinutuzumab and/or chlorambucil or a PI3K delta inhibitor
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
603 participants (actual)

Study arms

  • Experimental
    Arm A: Ublituximab + Umbralisib

    Participants received ublituximab, 150 milligrams (mg), intravenously (IV), on Day 1, 750 mg on Day 2, followed by 900 mg on Days 8 and 15 of Cycle 1 (cycle length=28 days), Day 1 of Cycles 2-6, and once every 3 cycles thereafter, along with umbralisib, 800 mg, orally, once daily during each cycle until disease progression, lack of tolerability, or until the treatment is commercially available or up to 87 months.

    Biological: Ublituximab · Drug: TGR-1202

  • Active comparator
    Arm B: Obinutuzumab + Chlorambucil

    Participants received Obinutuzumab 100 mg, IV on Day 1, 900 mg on Day 2, followed by 1000 mg on Days 8 and 15 of cycle 1 (cycle length = 28 days), Day 1 of Cycle 2-6 along with Chlorambucil 0.5 milligram per kilogram (mg/kg) tablet orally on Days 1 and 15 once daily during each cycle until disease progression, lack of tolerability, or until the treatment is commercially available or up to 87 months.

    Biological: Obinutuzumab · Drug: Chlorambucil

  • Experimental
    Arm C: Ublituximab

    Participants received ublituximab, 150 mg, IV, on Day 1, 750 mg on Day 2, followed by 900 mg on Days 8 and 15 of Cycle 1 (cycle length=28 days), Day 1 of Cycles 2-6, and once every 3 cycles thereafter, until disease progression, lack of tolerability, or until the treatment is commercially available or up to 87 months.

    Biological: Ublituximab

  • Experimental
    Arm D: Umbralisib

    Participants received umbralisib, 800 mg tablets, orally, once daily during each cycle (cycle length= 28 days) until removal from study or up to 87 months.

    Drug: TGR-1202

Interventions

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS) Per International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Criteria

    PFS was defined as the interval from enrollment to the earlier of the first documentation of definitive disease progression (PD) or death from any cause. PD was appearance of new nodes \>1.5 centimetres (cm) in the longest diameter (LD) and \>1.0 in longest perpendicular diameter (LPD), new or recurrent hepatomegaly or splenomegaly, new or reappearance of an unequivocal extra-nodal lesion, ≥50% increase from the nadir in the sum of products of diameters (SPD) of target lesions, ≥50% increase in the LD of an individual node or extra-nodal mass, splenic/hepatic enlargement of ≥50% from nadir, unequivocal increase in the size of non-target disease, transformation to a more aggressive histology, decrease in platelet count or Hgb, \>50% decrease from the highest on-study platelet count, \>20 grams per Liter (g/L) decrease from the highest on-study hemoglobin (Hgb).

    Time frame: From enrolment to the earlier of the first documentation of definitive disease progression (PD) or death (Up to 87 months)

Secondary outcomes

  1. Overall Response Rate (ORR) Per iwCLL Criteria

    ORR=percent of participants who achieve complete response (CR), complete response with incomplete marrow recovery (CRi), partial response (PR) or nodular partial response (nPR).CR: No evidence of new disease; Absolute lymphocyte count(ALC)\<4x10\^9/liter(L);Regression of all target nodal masses to ≤1.5cm in LD;Normal spleen,liver size;Regression to normal of all nodal non-target disease and disappearance of all detectable;Non-nodal,non-target disease;Morphologically negative bone marrow;No lymphoid nodules;ANC \>1.5x10\^9/L,platelets≥100x10\^9/L,Hgb≥110 g/L.PR:No evidence of new disease; Response in 2 of following if abnormal at baseline: ALC\<4x10\^9/L or ≥50% decrease from baseline in sum of products of target nodal lesions;splenomegaly; hepatomegaly;≥50% decrease from baseline in CLL marrow infiltrate/B-lymphoid nodules;response in any 1: ANC\>1.5x10\^9/L, platelets\>100x10\^9/L,Hgb\>110g/L or ≥50% increase over baseline in any of these.CRi:for CR except with ANC\<1000/µL and/or platelets\<100.

    Time frame: Up to 87 months

  2. Complete Response (CR) Rate

    The CR rate is defined as the percentage of participants with a best overall response of complete response (CR) or complete response with incomplete marrow recovery (CRi). CR: No evidence of new disease; Absolute lymphocyte count(ALC)\<4x10\^9/L; Regression of all target nodal masses to ≤1.5 cm in LD; Normal spleen,liver size; Regression to normal of all nodal non-target disease and disappearance of all detectable; Non-nodal, non-target disease; Morphologically negative bone marrow; No lymphoid nodules; ANC\>1.5x10\^9/L,platelets≥100x10\^9/L,hemoglobin (Hgb)≥110 g/L. CRi was as for CR except with ANC \<1000/µL and/or platelets \<100,000/µL.

    Time frame: Up to 87 months

  3. Minimal Residual Disease (MRD) Negativity Rate

    MRD negativity rate is defined as the percentage of participants who are MRD negative. If a participant was determined to be MRD negative by peripheral blood, a bone marrow aspirate was obtained to assess MRD in the bone marrow.

    Time frame: From Cycle 6 until Cycle 15 (cycle length=28 days) up to approximately 81.5 months

  4. Duration of Response (DOR)

    DOR is defined as the interval from the first documentation of CR, CRi, PR, or nPR to the earlier of the first documentation of definitive disease progression or death from any cause.

    Time frame: From first documentation of response to study treatment till disease progression/death (up to approximately 87 months)

  5. Number of Participants Experiencing at Least One Treatment-Emergent Adverse Event (TEAE)

    An adverse event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product. An AE does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporarily associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAE is any AE that occur after first dosing of study medication and through the end of the study or through 30 days after the last dose of study treatment, or is considered treatment-related regardless of the start date of the event, or is present before first dosing of study medication but worsens in intensity or the investigator subsequently considers treatment-related.

    Time frame: From first dose of study treatment up to end of study (up to approximately 87 months)

07

Results

Posted May 7, 2024
Limitations and caveats
Due to sponsor's business decision, the clinical trial was terminated by the sponsor prematurely. As such, the study results are reflective of the data captured to the time of study termination and with limited data verification.

Participant flow

Participants took part in the study at multiple investigative sites in the United States, Israel, Italy, Poland, Russian Federation, Spain and the United Kingdom from 19 November 2015 to 22 February 2023.

Participant flow — Overall Study
MilestoneExperimental: Arm A: Ublituximab + UmbralisibActive Comparator: Arm B: Obinutuzumab + ChlorambucilExperimental: Arm C: UblituximabExperimental: Arm D: Umbralisib
Started2102119191
Safety population2062009186
Completed0000
Not completed2102119191
Withdrew: Adverse event1612713
Withdrew: Death29101111
Withdrew: Initiation of non-protocol intervention5300
Withdrew: Investigator's decision111566
Withdrew: Lack of efficacy0011
Withdrew: Lost to follow-up2212
Withdrew: Progressive disease confirmed by central radiology751133843
Withdrew: Site terminated by sponsor2912135
Withdrew: Withdrawal by subject of consent or to discontinue treatment292465
Withdrew: Reason not specified3745
Withdrew: Unknown/missing101340
Withdrew: Non-compliance with study1000

Outcome measures

PrimaryProgression-Free Survival (PFS) Per International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Criteria

PFS was defined as the interval from enrollment to the earlier of the first documentation of definitive disease progression (PD) or death from any cause. PD was appearance of new nodes \>1.5 centimetres (cm) in the longest diameter (LD) and \>1.0 in longest perpendicular diameter (LPD), new or recurrent hepatomegaly or splenomegaly, new or reappearance of an unequivocal extra-nodal lesion, ≥50% increase from the nadir in the sum of products of diameters (SPD) of target lesions, ≥50% increase in the LD of an individual node or extra-nodal mass, splenic/hepatic enlargement of ≥50% from nadir, unequivocal increase in the size of non-target disease, transformation to a more aggressive histology, decrease in platelet count or Hgb, \>50% decrease from the highest on-study platelet count, \>20 grams per Liter (g/L) decrease from the highest on-study hemoglobin (Hgb).

Time frame:
From enrolment to the earlier of the first documentation of definitive disease progression (PD) or death (Up to 87 months)
Reported as:
Median · Months
Progression-Free Survival (PFS) Per International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Criteria
MonthsExperimental: Arm A: Ublituximab + UmbralisibActive Comparator: Arm B: Obinutuzumab + ChlorambucilExperimental: Arm C: UblituximabExperimental: Arm D: Umbralisib
Progression-Free Survival (PFS) Per International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Criteria33.2 (27.7 to 39.6)17.5 (16.6 to 22.6)32.9 (19.1 to 45.0)22.4 (17.2 to 34.7)
SecondaryOverall Response Rate (ORR) Per iwCLL Criteria

ORR=percent of participants who achieve complete response (CR), complete response with incomplete marrow recovery (CRi), partial response (PR) or nodular partial response (nPR).CR: No evidence of new disease; Absolute lymphocyte count(ALC)\<4x10\^9/liter(L);Regression of all target nodal masses to ≤1.5cm in LD;Normal spleen,liver size;Regression to normal of all nodal non-target disease and disappearance of all detectable;Non-nodal,non-target disease;Morphologically negative bone marrow;No lymphoid nodules;ANC \>1.5x10\^9/L,platelets≥100x10\^9/L,Hgb≥110 g/L.PR:No evidence of new disease; Response in 2 of following if abnormal at baseline: ALC\<4x10\^9/L or ≥50% decrease from baseline in sum of products of target nodal lesions;splenomegaly; hepatomegaly;≥50% decrease from baseline in CLL marrow infiltrate/B-lymphoid nodules;response in any 1: ANC\>1.5x10\^9/L, platelets\>100x10\^9/L,Hgb\>110g/L or ≥50% increase over baseline in any of these.CRi:for CR except with ANC\<1000/µL and/or platelets\<100.

Time frame:
Up to 87 months
Reported as:
Number · percentage of participants
Overall Response Rate (ORR) Per iwCLL Criteria
percentage of participantsExperimental: Arm A: Ublituximab + UmbralisibActive Comparator: Arm B: Obinutuzumab + ChlorambucilExperimental: Arm C: UblituximabExperimental: Arm D: Umbralisib
Overall Response Rate (ORR) Per iwCLL Criteria83.368.742.961.5
SecondaryComplete Response (CR) Rate

The CR rate is defined as the percentage of participants with a best overall response of complete response (CR) or complete response with incomplete marrow recovery (CRi). CR: No evidence of new disease; Absolute lymphocyte count(ALC)\<4x10\^9/L; Regression of all target nodal masses to ≤1.5 cm in LD; Normal spleen,liver size; Regression to normal of all nodal non-target disease and disappearance of all detectable; Non-nodal, non-target disease; Morphologically negative bone marrow; No lymphoid nodules; ANC\>1.5x10\^9/L,platelets≥100x10\^9/L,hemoglobin (Hgb)≥110 g/L. CRi was as for CR except with ANC \<1000/µL and/or platelets \<100,000/µL.

Time frame:
Up to 87 months
Reported as:
Number · percentage of participants
Complete Response (CR) Rate
percentage of participantsExperimental: Arm A: Ublituximab + UmbralisibActive Comparator: Arm B: Obinutuzumab + ChlorambucilExperimental: Arm C: UblituximabExperimental: Arm D: Umbralisib
Complete Response (CR) Rate5.71.43.30
SecondaryMinimal Residual Disease (MRD) Negativity Rate

MRD negativity rate is defined as the percentage of participants who are MRD negative. If a participant was determined to be MRD negative by peripheral blood, a bone marrow aspirate was obtained to assess MRD in the bone marrow.

Time frame:
From Cycle 6 until Cycle 15 (cycle length=28 days) up to approximately 81.5 months
Reported as:
Number · percentage of participants
Minimal Residual Disease (MRD) Negativity Rate
percentage of participantsExperimental: Arm A: Ublituximab + UmbralisibActive Comparator: Arm B: Obinutuzumab + ChlorambucilExperimental: Arm C: UblituximabExperimental: Arm D: Umbralisib
Minimal Residual Disease (MRD) Negativity Rate29.034.636.35.5
SecondaryDuration of Response (DOR)

DOR is defined as the interval from the first documentation of CR, CRi, PR, or nPR to the earlier of the first documentation of definitive disease progression or death from any cause.

Time frame:
From first documentation of response to study treatment till disease progression/death (up to approximately 87 months)
Reported as:
Median · months
Duration of Response (DOR)
monthsExperimental: Arm A: Ublituximab + UmbralisibActive Comparator: Arm B: Obinutuzumab + ChlorambucilExperimental: Arm C: UblituximabExperimental: Arm D: Umbralisib
Duration of Response (DOR)32.9 (27.8 to 39.4)21.9 (14.6 to 26.6)47.5 (40.3 to 57.8)29.3 (17.1 to 36.5)
SecondaryNumber of Participants Experiencing at Least One Treatment-Emergent Adverse Event (TEAE)

An adverse event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product. An AE does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporarily associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAE is any AE that occur after first dosing of study medication and through the end of the study or through 30 days after the last dose of study treatment, or is considered treatment-related regardless of the start date of the event, or is present before first dosing of study medication but worsens in intensity or the investigator subsequently considers treatment-related.

Time frame:
From first dose of study treatment up to end of study (up to approximately 87 months)
Reported as:
Count of participants · Participants
Number of Participants Experiencing at Least One Treatment-Emergent Adverse Event (TEAE)
ParticipantsExperimental: Arm A: Ublituximab + UmbralisibActive Comparator: Arm B: Obinutuzumab + ChlorambucilExperimental: Arm C: UblituximabExperimental: Arm D: Umbralisib
Number of Participants Experiencing at Least One Treatment-Emergent Adverse Event (TEAE)2051958886

Adverse events

Collected over From first dose of study treatment up to end of study (up to approximately 87 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Experimental: Arm A: Ublituximab + Umbralisib82/206 (39.8%)118/206 (57.3%)205/206 (99.5%)
Active Comparator: Arm B: Obinutuzumab + Chlorambucil40/200 (20%)47/200 (23.5%)189/200 (94.5%)
Experimental: Arm C: Ublituximab25/91 (27.5%)33/91 (36.3%)84/91 (92.3%)
Experimental: Arm D: Umbralisib29/86 (33.7%)34/86 (39.5%)84/86 (97.7%)
Most frequent serious events
Showing 10 of 206
Most frequent serious events
EventExperimental: Arm A: Ublituximab + UmbralisibActive Comparator: Arm B: Obinutuzumab + ChlorambucilExperimental: Arm C: UblituximabExperimental: Arm D: Umbralisib
PneumoniaInfections and infestations21/2064/2004/910/86
COVID-19 pneumoniaInfections and infestations10/2060/2008/910/86
COVID-19Infections and infestations13/2060/2004/911/86
SepsisInfections and infestations7/2061/2004/912/86
AnaemiaBlood and lymphatic system disorders2/2062/2001/913/86
Urinary tract infectionInfections and infestations5/2061/2001/911/86
Febrile neutropeniaBlood and lymphatic system disorders3/2062/2002/912/86
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/2060/2001/912/86
DizzinessNervous system disorders2/2060/2000/912/86
Atrial fibrillationCardiac disorders3/2060/2002/910/86
Most frequent other events
Showing 10 of 88
Most frequent other events
EventExperimental: Arm A: Ublituximab + UmbralisibActive Comparator: Arm B: Obinutuzumab + ChlorambucilExperimental: Arm C: UblituximabExperimental: Arm D: Umbralisib
DiarrhoeaGastrointestinal disorders118/20645/20024/9154/86
NauseaGastrointestinal disorders105/20675/20027/9134/86
Infusion related reactionInjury, poisoning and procedural complications92/20649/20036/910/86
NeutropeniaBlood and lymphatic system disorders70/20679/20025/9115/86
FatigueGeneral disorders76/20660/20028/9122/86
CoughRespiratory, thoracic and mediastinal disorders62/20636/20018/9118/86
ChillsGeneral disorders52/20633/20025/9112/86
HeadacheNervous system disorders56/20636/20018/9117/86
PyrexiaGeneral disorders53/20638/20022/9111/86
Upper respiratory tract infectionInfections and infestations48/20626/20016/9118/86

Baseline characteristics

The Intent-to-Treat (ITT) population included all randomized participants, regardless of administration of study treatment (ublituximab, TGR-1202, obinutuzumab + chlorambucil, or ublituximab + TGR-1202).

Age, Continuous
Age, Continuous(years)Experimental: Arm A: Ublituximab + UmbralisibActive Comparator: Arm B: Obinutuzumab + ChlorambucilExperimental: Arm C: UblituximabExperimental: Arm D: UmbralisibTotal
Mean66.2 (39 to 88)67.1 (36 to 91)67.6 (40 to 88)66.3 (43 to 86)66.8 (36 to 91)
Sex: Female, Male
Sex: Female, Male(Participants)Experimental: Arm A: Ublituximab + UmbralisibActive Comparator: Arm B: Obinutuzumab + ChlorambucilExperimental: Arm C: UblituximabExperimental: Arm D: UmbralisibTotal
Female75672330195
Male1351446861408
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Experimental: Arm A: Ublituximab + UmbralisibActive Comparator: Arm B: Obinutuzumab + ChlorambucilExperimental: Arm C: UblituximabExperimental: Arm D: UmbralisibTotal
Hispanic or Latino352313
Not Hispanic or Latino1931948683556
Unknown or Not Reported14123534
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Experimental: Arm A: Ublituximab + UmbralisibActive Comparator: Arm B: Obinutuzumab + ChlorambucilExperimental: Arm C: UblituximabExperimental: Arm D: UmbralisibTotal
American Indian or Alaska Native01001
Asian01113
Native Hawaiian or Other Pacific Islander10001
Black or African American965525
White1891958382549
Multiple20002
Other11024
Not Reported872118
08

Study locations

154 sites
  • TG Therapeutics Investigational Trial Site
    Huntsville, Alabama 35805, United States
  • TG Therapeutics Investigational Trial Site
    Mobile, Alabama 36604, United States
  • TG Therapeutics Investigational Trial Site
    Chandler, Arizona 85224, United States
  • TG Therapeutics Investigational Trial Site
    Phoenix, Arizona 85016, United States
  • TG Therapeutics Investigational Trial Site
    Tucson, Arizona 85711, United States
  • TG Therapeutics Investigational Trial Site
    Fayetteville, Arkansas 72703, United States
  • TG Therapeutics Investigational Trial Site
    Concord, California 94520, United States
  • TG Therapeutics Investigational Trial Site
    Duarte, California 91010, United States
  • TG Therapeutics Investigational Trial Site
    Greenbrae, California 94904, United States
  • TG Therapeutics Investigational Trial Site
    Pismo Beach, California 93449, United States
  • TG Therapeutics Investigational Trial Site
    Pleasanton, California 94588, United States
  • TG Therapeutics Investigational Trial Site
    San Diego, California 92120, United States
  • TG Therapeutics Investigational Trial Site
    Santa Barbara, California 93105, United States
  • TG Therapeutics Investigational Trial Site
    Whittier, California 90603, United States
  • TG Therapeutics Investigational Trial Site
    Aurora, Colorado 80012, United States
  • TG Therapeutics Investigational Trial Site
    Denver, Colorado 80218, United States
  • TG Therapeutics Investigational Trial Site
    Bridgeport, Connecticut 06606, United States
  • TG Therapeutics Investigational Trial Site
    New Haven, Connecticut 06519, United States
  • TG Therapeutics Investigational Trial Site
    Stamford, Connecticut 06904, United States
  • TG Therapeutics Investigational Trial Site
    Newark, Delaware 19713, United States
  • TG Therapeutics Investigational Trial Site
    Boca Raton, Florida 33486, United States
  • TG Therapeutics Investigational Trial Site
    Fort Myers, Florida 33916, United States
  • TG Therapeutics Investigational Trial Site
    Jacksonville, Florida 32204, United States
  • TG Therapeutics Investigational Trial Site
    Jacksonville, Florida 32256, United States
  • TG Therapeutics Investigational Trial Site
    Ocala, Florida 34471, United States
  • TG Therapeutics Investigational Trial Site
    Pensacola, Florida 32504, United States
  • TG Therapeutics Investigational Trial Site
    Saint Petersburg, Florida 33705, United States
  • TG Therapeutics Investigational Trial Site
    Tallahassee, Florida 32308, United States
  • TG Therapeutics Investigational Trial Site
    Tampa, Florida 33612, United States
  • TG Therapeutics Investigational Trial Site
    West Palm Beach, Florida 33407, United States
  • TG Therapeutics Investigational Trial Site
    Albany, Georgia 31701, United States
  • TG Therapeutics Investigational Trial Site
    Macon, Georgia 31201, United States
  • TG Therapeutics Investigational Trial Site
    Chicago, Illinois 60612, United States
  • TG Therapeutics Investigational Trial Site
    Decatur, Illinois 62526, United States
  • TG Therapeutics Investigational Trial Site
    Maywood, Illinois 60153, United States
  • TG Therapeutics Investigational Trial Site
    Niles, Illinois 60714, United States
  • TG Therapeutics Investigational Trial Site
    Peoria, Illinois 61615, United States
  • TG Therapeutics Investigational Trial Site
    Swansea, Illinois, United States
  • TG Therapeutics Investigational Trial Site
    Urbana, Illinois 61801, United States
  • TG Therapeutics Investigational Trial Site
    Fort Wayne, Indiana 46804, United States
  • TG Therapeutics Investigational Trial Site
    Indianapolis, Indiana 46237, United States
  • TG Therapeutics Investigational Trial Site
    Ames, Iowa 50010, United States
  • TG Therapeutics Investigational Trial Site
    Cedar Rapids, Iowa 52403, United States
  • TG Therapeutics Investigational Trial Site
    Kansas City, Kansas 64132, United States
  • TG Therapeutics Investigational Trial Site
    Westwood, Kansas 66210, United States
  • TG Therapeutics Investigational Trial Site
    Louisville, Kentucky 40207, United States
  • TG Therapeutics Investigational Trial Site
    Baltimore, Maryland 21202, United States
  • TG Therapeutics Investigational Trial Site
    Baltimore, Maryland 21215, United States
  • TG Therapeutics Investigational Trial Site
    Bethesda, Maryland 20817, United States
  • TG Therapeutics Investigational Trial Site
    Columbia, Maryland 21044, United States
  • TG Therapeutics Investigational Trial Site
    Boston, Massachusetts 02111, United States
  • TG Therapeutics Investigational Trial Site
    Worcester, Massachusetts 01608, United States
  • TG Therapeutics Investigational Trial Site
    Ann Arbor, Michigan 48106, United States
  • TG Therapeutics Investigational Trial Site
    Detroit, Michigan 48202, United States
  • TG Therapeutics Investigational Trial Site
    Jackson, Michigan 49201, United States
  • TG Therapeutics Investigational Trial Site
    Saint Louis Park, Minnesota 55416, United States
  • TG Therapeutics Investigational Trial Site
    Columbia, Missouri 65212, United States
  • TG Therapeutics Investigational Trial Site
    Kansas City, Missouri, United States
  • TG Therapeutics Investigational Trial Site
    Lincoln, Nebraska 68510, United States
  • TG Therapeutics Investigational Trial Site
    Las Vegas, Nevada 89119, United States
  • TG Therapeutics Investigational Trial Site
    Lebanon, New Hampshire 03756, United States
  • TG Therapeutics Investigational Trial Site
    Morristown, New Jersey 07962, United States
  • TG Therapeutics Investigational Trial Site
    Somerville, New Jersey 00876, United States
  • TG Therapeutics Investigational Trial Site
    East Setauket, New York 11733, United States
  • TG Therapeutics Investigational Trial Site
    Glens Falls, New York 12801, United States
  • TG Therapeutics Investigational Trial Site
    Syracuse, New York 13210, United States
  • TG Therapeutics Investigational Trial Site
    Charlotte, North Carolina 28204, United States
  • TG Therapeutics Investigational Trial Site
    Durham, North Carolina 27710, United States
  • TG Therapeutics Investigational Trial Site
    Durham, North Carolina, United States
  • TG Therapeutics Investigational Trial Site
    Hickory, North Carolina 28602, United States
  • TG Therapeutics Investigational Trial Site
    Kinston, North Carolina 28501, United States
  • TG Therapeutics Investigational Trial Site
    Raleigh, North Carolina 27607, United States
  • TG Therapeutics Investigational Trial Site
    Washington, North Carolina 27889, United States
  • TG Therapeutics Investigational Trial Site
    Canton, Ohio 44718, United States
  • TG Therapeutics Investigational Trial Site
    Cincinnati, Ohio 45236, United States
  • TG Therapeutics Investigational Trial Site
    Toledo, Ohio 43623, United States
  • TG Therapeutics Investigational Trial Site
    Portland, Oregon 97227, United States
  • TG Therapeutics Investigational Trial Site
    Portland, Oregon 97239, United States
  • TG Therapeutics Investigational Trial Site
    Springfield, Oregon 97477, United States
  • TG Therapeutics Investigational Trial Site
    Camp Hill, Pennsylvania 17011, United States
  • TG Therapeutics Investigational Trial Site
    Danville, Pennsylvania 17822, United States
  • TG Therapeutics Investigational Trial Site
    Hershey, Pennsylvania 17033, United States
  • TG Therapeutics Investigational Trial Site
    Philadelphia, Pennsylvania 19106, United States
  • TG Therapeutics Investigational Trial Site
    Pittsburgh, Pennsylvania 15224, United States
  • TG Therapeutics Investigational Trial Site
    Pittsburgh, Pennsylvania 15232, United States
  • TG Therapeutics Investigational Trial Site
    Pawtucket, Rhode Island 00286, United States
  • TG Therapeutics Investigational Trial Site
    Greenville, South Carolina 29615, United States
  • TG Therapeutics Investigational Trial Site
    Sioux Falls, South Dakota 57105, United States
  • TG Therapeutics Investigational Trial Site
    Watertown, South Dakota 57201, United States
  • TG Therapeutics Investigational Trial Site
    Chattanooga, Tennessee 37404, United States
  • TG Therapeutics Investigational Trial Site
    Nashville, Tennessee 37203, United States
  • TG Therapeutics Investigational Trial Site
    Austin, Texas 78705, United States
  • TG Therapeutics Investigational Trial Site
    Bedford, Texas 76022, United States
  • TG Therapeutics Investigational Trial Site
    Fort Worth, Texas 76104, United States
  • TG Therapeutics Investigational Trial Site
    Houston, Texas 77030, United States
  • TG Therapeutics Investigational Trial Site
    San Antonio, Texas 78217, United States
  • TG Therapeutics Investigational Trial Site
    San Antonio, Texas 78229, United States
  • TG Therapeutics Investigational Trial Site
    Tyler, Texas 75702, United States
  • TG Therapeutics Investigational Trial Site
    Ogden, Utah 84405, United States
  • TG Therapeutics Investigational Trial Site
    Blacksburg, Virginia 24060, United States

Showing the first 100 of 154 sites across 7 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2015 to primary completion in Feb 2023, 87 months.

Results were first posted in May 2024, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2015
First posted
Nov 23, 2015
StartActual
Nov 19, 2015
Primary completionActual
Feb 22, 2023
CompletionActual
Feb 22, 2023
Results first posted
May 7, 2024
Last update
Dec 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02612311
Responsible party
Sponsor
First posted
Nov 23, 2015
Start date
Nov 19, 2015
Primary completion
Feb 22, 2023
Completion
Feb 22, 2023
Results posted
May 7, 2024
Last update
Dec 13, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ublituximab · Umbralisib

Start the discussion